Decitabine: Phase I data; Phase III for myelodysplastic syndrome (MDS)

In a U.S. Phase I trial, 18% (8/45) of patients that completed at least one

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE